Citadel Advisors
NSPR icon

Citadel Advisors’s InspireMD NSPR Stock Holding History

Citadel Advisors’s Portfolio NSPR Stock Details NSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-100
Closed -$230 – 15043
2024
Q1 		$230 Buy
+100
New +$270 ﹤0.01% 14387
2023
Q1 		– Sell
-100
Closed -$86 – 15241
2022
Q4 		$86 Buy
+100
New +$113 ﹤0.01% 14766

Other funds holding NSPR

RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
AF
Affiance Financial St. Louis Park, Minnesota $695M AUM 17.33% 1-Year Est. Return

Citadel Advisors's NSPR Position: Q2 2026 in Review

Citadel Advisors sold out of InspireMD (NSPR) in Q2 2026, closing a stake of 65,750 shares — an estimated $69.7K sold.

Citadel Advisors first reported a position in NSPR in Q1 2018 and held it in 13 quarters. The position peaked at $345K in Q4 2025. 37 funds tracked by Wall St. Rank hold NSPR as of Q2 2026.

  • Citadel Advisors reported no remaining InspireMD position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 65,750 InspireMD shares in Q2 2026, an estimated $69.7K.
  • Citadel Advisors first reported a position in InspireMD in Q1 2018 and held it in 13 quarters.
  • Citadel Advisors's InspireMD position peaked at $345K in Q4 2025.
  • 37 funds tracked by Wall St. Rank held InspireMD as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.